Liu Fanwei, Liu Bowen, Xu Shanshan, Ni Yinhua, Liu Xiaoli
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China.
Department of Anesthesia, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China.
Endocr J. 2025 Jan 6;72(1):53-67. doi: 10.1507/endocrj.EJ24-0317. Epub 2024 Oct 1.
Significant overlap in the epidemiology and coinfection of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) has been identified, which accelerates the development of severe liver cirrhosis and hepatocellular carcinoma worldwide. Interferon-α (IFN-α), a cytokine with antiviral properties, exerts profound physiological effects on innate immunity by regulating interferon-stimulated genes (ISGs) within cells. However, the underlying mechanism of IFN-α in hepatic inflammation remains to be fully elucidated. Here, we utilized LO2 cells treated with the recombinant IFN-α protein and conducted microRNA (miR) sequencing. MiR-122-3p and miR-122-5p_R+1 were the most enriched miRNAs involved in the pathogenesis of IFN-α-induced inflammatory responses and were significantly downregulated by IFN-α treatment. Furthermore, we identified interferon induced protein with tetratricopeptide repeats 1 (IFIT1) as a potential target gene of miR-122. IFN-α markedly increased the expression of proinflammatory cytokines and fibrogenic genes but decreased the mRNA expression of ISGs. Additionally, IFN-α significantly activated the NF-κB p-p65, MAPK p-p38, and Jak/STAT pathways to trigger inflammation. Importantly, supplementation with a miR-122 mimic significantly alleviated IFN-α-induced inflammation and induced IFIT1 expression in LO2 cells. Conversely, the suppression of miR-122 markedly exacerbated the inflammatory response triggered by IFN-α. Furthermore, silencing IFIT1 via an siRNA elicited an inflammatory response, whereas IFIT1 overexpression ameliorated hepatic inflammation and fibrosis in a manner comparable to that induced by IFN-α treatment. Taken together, our findings suggest that miR-122 and its target, IFIT1, reciprocally regulate the inflammatory response associated with IFN through the Jak/STAT pathway.
已发现慢性乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)在流行病学和合并感染方面存在显著重叠,这在全球范围内加速了严重肝硬化和肝细胞癌的发展。干扰素-α(IFN-α)是一种具有抗病毒特性的细胞因子,通过调节细胞内的干扰素刺激基因(ISG)对先天免疫发挥深远的生理作用。然而,IFN-α在肝脏炎症中的潜在机制仍有待充分阐明。在此,我们利用重组IFN-α蛋白处理的LO2细胞进行了微小RNA(miR)测序。MiR-122-3p和miR-122-5p_R+1是参与IFN-α诱导的炎症反应发病机制的最丰富的微小RNA,并且通过IFN-α处理显著下调。此外,我们确定四肽重复序列1干扰素诱导蛋白(IFIT1)为miR-122的潜在靶基因。IFN-α显著增加促炎细胞因子和纤维化基因的表达,但降低ISG的mRNA表达。此外,IFN-α显著激活NF-κB p-p65、MAPK p-p38和Jak/STAT途径以引发炎症。重要的是,补充miR-122模拟物可显著减轻IFN-α诱导的炎症并诱导LO2细胞中IFIT1的表达。相反,抑制miR-122显著加剧了IFN-α引发的炎症反应。此外,通过小干扰RNA沉默IFIT1引发炎症反应,而IFIT1过表达以与IFN-α处理诱导的方式相当的方式改善肝脏炎症和纤维化。综上所述,我们的研究结果表明,miR-122及其靶标IFIT1通过Jak/STAT途径相互调节与IFN相关的炎症反应。